CryoTherapeutics provides an integrated console and balloon catheter system that delivers controlled cryotherapy to high‑risk, non‑obstructive coronary plaques.
Funding
$10.8M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current treatments for high‑risk, non‑obstructive coronary plaque rely on stenting, which carries significant procedural risks and uncertain outcomes, while many vulnerable plaques remain undiagnosed until they cause a heart attack.
Solution
CryoTherapeutics offers a dedicated console and catheter system that delivers controlled cryotherapy to coronary plaques. The console inflates a balloon catheter and pumps a cooling agent to lower the temperature of the solution inside the balloon to a precise range of –10 °C to –20 °C. This temperature‑regulated cryoenergy stabilizes vulnerable plaque without the need for permanent implants. By providing real‑time temperature control and automated balloon inflation, the system enables interventional cardiologists to perform safer, targeted plaque treatment during routine catheter procedures.
Target Audience
Primary customers are interventional cardiologists and cardiac catheterization labs seeking a minimally invasive alternative to stenting for treating high‑risk, non‑obstructive coronary plaques.
Features
- Integrated console that synchronizes balloon inflation with precise delivery of cooling agent
- Temperature control loop maintaining target plaque temperatures between –10 °C and –20 °C
- Catheter design optimized for delivering cryoenergy to coronary arteries
- Automated monitoring of cooling agent flow and balloon pressure to ensure consistent treatment
- Compatibility with standard intravascular imaging workflows for lesion targeting